作者: Judy S. Crabtree , Xiaochun Zhang , Bryan J. Peano , Zhiming Zhang , Richard C. Winneker
DOI: 10.1016/J.JSBMB.2006.06.017
关键词: Internal medicine 、 Tanaproget 、 Agonist 、 Receptor 、 Endocrinology 、 Uterus 、 Estrogen 、 Mammary gland 、 Downregulation and upregulation 、 Progesterone receptor 、 Biology 、 Clinical biochemistry 、 Molecular medicine 、 Cell biology 、 Biochemistry 、 Molecular biology 、 Endocrinology, Diabetes and Metabolism
摘要: We have identified mRNA markers of estradiol and progesterone action in the mouse mammary gland uterus to establish an vivo model for evaluation novel potentially tissue selective estrogens progestins. Gene chip analysis from ovariectomized (OVX) mice treated with vehicle (V), 17beta-estradiol (E2), (P) or E2+P 7 days defensinbeta1 (Defbeta1) indoleamine-pyrrole 2,3 dioxygenase (INDO) as E2 P gland, serine protease inhibitor, Kazal type 3 (Spink3) G protein-coupled receptor 105 (GPR105) uterus. Defbeta1 Spink3 are both upregulated by E2+P, whereas INDO GPR105 a complementary profile upregulation alone suppression effect P. Quantitative RT-PCR was concordant histological changes. Using this model, medroxyprogesterone acetate (MPA) tanaproget (TNPR), nonsteroidal agonist, were evaluated found no marked selectivity relative progesterone. In addition, ERalpha ligand propyl pyrazole triol (PPT) ERbeta ligands ERB-041 WAY-202196 on endpoints histology expression, showed that stimulation is necessary sufficient eliciting estradiol-mediated changes gland.